Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-36658
Titel: Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients
VerfasserIn: Karl, Florian M.
Holle, Rolf
Bals, Robert
Greulich, Timm
Jörres, Rudolf A.
Karch, Annika
Koch, Armin
Karrasch, Stefan
Leidl, Reiner
Schulz, Holger
Vogelmeier, Claus
Wacker, Margarethe E.
Sprache: Englisch
Titel: Respiratory Research
Bandnummer: 18
Heft: 1
Verlag/Plattform: BMC
Erscheinungsjahr: 2017
Freie Schlagwörter: COPD
Alpha-1-Antitrypsin Deficiency
Direct costs
Indirect costs
Health-related quality of life
Augmentation therapy
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Background: Alpha-1-Antitrypsin Deficiency (AATD) is an economically unexplored genetic disease. Methods: Direct and indirect costs (based on self-reported information on healthcare utilization) and health-related quality of life (HRQL, as assessed by SGRQ, CAT, and EQ-5D-3 L) were compared between 131 AATD patients (106 with, 25 without augmentation therapy (AT)) and 2,049 COPD patients without AATD participating in the COSYCONET COPD cohort. The medication costs of AT were excluded from all analyses to reveal differences associated with morbidity profiles. The association of AATD (with/without AT) with costs or HRQL was examined using generalized linear regression modelling (GLM) adjusting for age, sex, GOLD grade, BMI, smoking status, education and comorbidities. Results: Adjusted mean direct annual costs were €6,099 in AATD patients without AT, €7,117 in AATD patients with AT (excluding costs for AT), and €7,460 in COPD patients without AATD. AATD with AT was significantly associated with higher outpatient (+273%) but lower inpatient (−35%) and medication costs (−10%, disregarding AT) compared with COPD patients without AATD. There were no significant differences between groups regarding indirect costs and HRQL. Conclusion: Apart from AT costs, AATD patients tended to have lower, though not significant, overall costs and similar HRQL compared to COPD patients without AATD. AT was not associated with lower costs or higher HRQL.
DOI der Erstveröffentlichung: 10.1186/s12931-017-0543-8
URL der Erstveröffentlichung: https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-017-0543-8
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-366581
hdl:20.500.11880/33298
http://dx.doi.org/10.22028/D291-36658
ISSN: 1465-993X
Datum des Eintrags: 6-Jul-2022
Bezeichnung des in Beziehung stehenden Objekts: Additional files
In Beziehung stehendes Objekt: https://static-content.springer.com/esm/art%3A10.1186%2Fs12931-017-0543-8/MediaObjects/12931_2017_543_MOESM1_ESM.doc
https://static-content.springer.com/esm/art%3A10.1186%2Fs12931-017-0543-8/MediaObjects/12931_2017_543_MOESM2_ESM.doc
https://static-content.springer.com/esm/art%3A10.1186%2Fs12931-017-0543-8/MediaObjects/12931_2017_543_MOESM3_ESM.doc
https://static-content.springer.com/esm/art%3A10.1186%2Fs12931-017-0543-8/MediaObjects/12931_2017_543_MOESM4_ESM.doc
https://static-content.springer.com/esm/art%3A10.1186%2Fs12931-017-0543-8/MediaObjects/12931_2017_543_MOESM5_ESM.doc
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Innere Medizin
Professur: M - Prof. Dr. Robert Bals
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Dateien zu diesem Datensatz:
Datei Beschreibung GrößeFormat 
s12931-017-0543-8.pdf629,93 kBAdobe PDFÖffnen/Anzeigen


Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons Creative Commons